Suven Pharmaceuticals has a good order-book, Venkat Jasti, Chairman and Chief Executive Officer (CEO), told CNBC-TV18.
The pharma company reported earnings for the September-ended quarter with growth led by the speciality chemicals segment. The company posted a 27 percent growth in revenue on a yearly basis.
“The only worry point for us is the cost of raw materials going up and also (its) non-availability. In addition to that, the problems are non-availability of vessels and price increases, quadrupling in transportation cost ― that’s the main worry. Otherwise, we have a very good order-book and good growth pattern for the next six months,” Jasti said.
However, the company does not pass on all input cost increases, said Jasti.
Also Read: Sun Pharma Q2FY22: Focus on core business continues, to maintain momentum in speciality biz
“We cannot pass on (prices) unlike generic companies because these are long-term contracts. Only when contracts are renewed can we get an increase in prices. And if it is more than 10 percent, then we can have a sharing agreement with the customers,” he said.
For the entire management interview, watch the video
(Edited by : Thomas Abraham)
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
